Revisiones sistemáticas relacionados a este tópico

loading
7 Referencias (7 articles) loading Revertir Estudificar

Revisión sistemática

No clasificado

Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis.

Revista International journal of molecular sciences
Año 2023
Enlaces Pubmed DOI PubMed Central

Este artículo incluye 22 Estudios primarios 22 Estudios primarios (22 referencias)

Cargando información sobre las referencias
The aims of this systematic literature review (SLR) were to identify the effects of approved biological and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on synovial membrane of psoriatic arthritis (PsA) patients, and to determine the existence of histological/molecular biomarkers of response to therapy. A search was conducted on MEDLINE, Embase, Scopus, and Cochrane Library (PROSPERO:CRD42022304986) to retrieve data on longitudinal change of biomarkers in paired synovial biopsies and in vitro studies. A meta-analysis was conducted by adopting the standardized mean difference (SMD) as a measure of the effect. Twenty-two studies were included (19 longitudinal, 3 in vitro). In longitudinal studies, TNF inhibitors were the most used drugs, while, for in vitro studies, JAK inhibitors or adalimumab/secukinumab were assessed. The main technique used was immunohistochemistry (longitudinal studies). The meta-analysis showed a significant reduction in both CD3+ lymphocytes (SMD -0.85 [95% CI -1.23; -0.47]) and CD68+ macrophages (sublining, sl) (SMD -0.74 [-1.16; -0.32]) in synovial biopsies from patients treated for 4-12 weeks with bDMARDs. Reduction in CD3+ mostly correlated with clinical response. Despite heterogeneity among the biomarkers evaluated, the reduction in CD3+/CD68+sl cells during the first 3 months of treatment with TNF inhibitors represents the most consistent variation reported in the literature.

Revisión sistemática

No clasificado

Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: a systematic review

Revista Ther. Adv. Musculoskelet. Dis.
Año 2021
Enlaces Pubmed DOI PubMed Central

Este artículo incluye 44 Estudios primarios 44 Estudios primarios (44 referencias)

Cargando información sobre las referencias

Revisión sistemática

No clasificado

Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review.

Revista Expert review of clinical pharmacology
Año 2020
Enlaces Pubmed DOI

Este artículo incluye 27 Estudios primarios 28 Estudios primarios (27 referencias)

Cargando información sobre las referencias
Introduction: The management of Psoriatic arthritis (PsA) has evolved in the last decade with a significant increase in treatment options making the choice for clinicians difficult. Thus, the different factors of good prognosis for each treatment are presented in this review.Areas covered: Current available treatment and assessment tools for the response of treatment are presented. A systematic review of the literature, on Pubmed, Medline and Cochrane databases and abstracts from the last three EULAR and ACR annual conferences was performed. Factors associated with a good response to csDMARDs, tsDMARDs and bDMARDs are presented.Expert Opinion: Dactylitis and axial involvement are associated with a poor response to methotrexate. Leflunomide has shown better efficacy in the presence of established polyarticular involvement. TNF inhibitors are to be preferred in young men with an elevated CRP while obesity, high disease activity and long disease duration are factors associated with poor response. Apremilast and ustekinumab are more effective in mono and oligo articular disease. Abatacept is more effective in patients with high CRP, high disease activity and polyarticular involvement. Finally, there are no available data with the anti IL17 These factors are some arguments to help clinicians, but comparative study are needed to conclude.

Revisión sistemática

No clasificado

Diferencias Sexuales en el Tratamiento de la Artritis Psoriásica: Una Revisión Sistemática de la Literatura.

automatic
Revista The Israel Medical Association journal : IMAJ
Año 2016
Enlaces Pubmed

Este artículo incluye 9 Estudios primarios 9 Estudios primarios (9 referencias)

Cargando información sobre las referencias
La artritis psoriásica (PsA) es una afección inflamatoria crónica asociada con la psoriasis de la piel y manifiesta un amplio fenotipo clínico, con las diferencias propuestas entre los sexos. Los tratamientos actuales se basan en fármacos antirreumáticos tradicionales modificadores de la enfermedad (DMARD), y los agentes biológicos y los estudios han informado diferentes patrones de respuesta clínica en función de los factores de sexo. Nuestro objetivo fue identificar las diferencias entre los sexos en la tasa de retención de fármacos en pacientes con AP y realizó una investigación sistemática en las bases de datos MEDLINE, EMBASE y Cochrane (1979 a junio de 2015) para estudios sobre la efectividad (medida como tasa de retención de fármacos) Biológicos Se extrajeron los datos demográficos, así como las tasas de retención entre los sexos. De un total de 709 referencias recuperadas, incluimos 9 artículos para el análisis final. Sólo un estudio informó datos sobre DMARDs, mientras que ocho estudios informaron tasa de retención de factores biológicos de factor de necrosis antitumoral (TNF), principalmente infliximab, adalimumab y etanercept. No se informaron diferencias en las tasas de retención entre los sexos para el metotrexato, mientras que las mujeres manifestaron tasas de retención más bajas en comparación con los hombres con respecto al anti-TNF. Destacamos la necesidad de incluir las diferencias de sexo en el diagrama de flujo de la gestión de los pacientes con AP.

Revisión sistemática

No clasificado

Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review

Revista The Journal of rheumatology
Año 2014
Enlaces Pubmed DOI

Este artículo incluye 66 Estudios primarios 55 Estudios primarios (66 referencias)

Cargando información sobre las referencias
In 2009, GRAPPA published their first evidence-based recommendations for the treatment of psoriasis and psoriatic arthritis (PsA). Since then, new information has been published and drugs developed. We summarize evidence for the efficacy of available treatments for peripheral joint involvement in PsA. We performed a systematic review of current literature on the efficacy of different therapies, management, and therapeutic strategies for peripheral arthritis involvement in PsA, in order to provide information for the development of the new GRAPPA treatment recommendations.

Revisión sistemática

No clasificado

Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease?

Revista Drugs
Año 2014
Enlaces Pubmed DOI

Este artículo incluye 23 Estudios primarios 23 Estudios primarios (23 referencias)

Cargando información sobre las referencias
Psoriasis is an inflammatory disease associated with multiple comorbidities and cardiovascular risk factors. Patients with psoriasis have an increased risk of cardiovascular disease (CVD) and cardiovascular death. It has been proposed that overlapping mechanisms of systemic inflammation contribute to the link between psoriasis and cardiovascular disease. Some psoriasis treatments decrease systemic inflammation, but the effect of psoriasis treatments on heart disease is unknown. In this review of 23 original research publications, we present preliminary evidence that some psoriasis therapies improve cardiovascular biomarkers and the incidence of cardiovascular risk. Phototherapy may reduce some inflammatory cytokines, but there is little evidence for a decreased risk of CVD outcomes. Both methotrexate and tumour necrosis factor-α inhibitors improve cardiovascular inflammatory biomarkers and improve CVD outcomes. Short-term data on interleukin-12/23 inhibitors are varied, but most data suggest there is not an increase in cardiovascular events.

Revisión sistemática

No clasificado

Combination systemic therapies in psoriatic arthritis.

Autores Daly M , Alikhan A , Armstrong AW
Revista The Journal of dermatological treatment
Año 2011
Enlaces Pubmed DOI

Este artículo incluye 15 Estudios primarios 14 Estudios primarios (15 referencias)

Cargando información sobre las referencias
Psoriatic arthritis (PsA) is a chronic, progressive, and debilitating disorder. When monotherapy fails, combination therapy is necessary for the long-term management of these patients. There is currently no review on this subject, and the purpose of this study was to investigate and describe the current literature on combination therapy in PsA. A PubMed MeSH search was performed for psoriatic arthritis and combination therapy, which yielded at total of 83 articles. After excluding reviews and commentaries, and pursuing relevant citations, a total of 21 articles on the subject were found: one study of NSAIDs and methotrexate, three studies of cyclosporine and methotrexate, three studies of non-TNF biologic inhibitors (alefacept, ustekinumab) and methotrexate, and 14 studies of anti-TNF-inhibitors (etanercept, adalimumab, infliximab, golimumab) and methotrexate. The combination of cyclosporine and methotrexate reduces the dosages and also the side effects of each agent, allowing better disease control with less toxicity. Methotrexate in combination with biologic agents, either non-TNF inhibitors or anti-TNF inhibitors, may have a role in decreasing side effects, but it does not appear to improve clinical symptoms beyond those attained by biologic monotherapy.